Gastroenterology
Latest news
416 articles · 20 / page
Adjuvant Imatinib Significantly Extends Survival and Delays Recurrence in KIT Exon 9-Mutant GIST: Evidence from a Global Multicenter Cohort
This international multicenter study demonstrates that adjuvant imatinib therapy significantly improves both recurrence-free and overall survival in patients with resected KIT exon 9-mutant GIST, providing clarity on optimal management for
More is Not Always Better: The GOULASH Trial Challenges High-Energy Early Nutrition in Acute Pancreatitis
The multicentre GOULASH trial reveals that high-energy nutrition in the early phase of acute pancreatitis does not improve outcomes and may increase risks of organ failure and pain relapse compared to a gradual caloric increase, leading to
Stem Cell Therapy for Complex Perianal Fistulas: Why the ADMIRE CD II Trial Missed Its Mark
The ADMIRE CD II Phase 3 trial failed to show a significant benefit of darvadstrocel over placebo for complex perianal fistulas in Crohn’s disease, primarily due to an unexpectedly high remission rate in the placebo-controlled surgical arm.
Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers
A multicentre cohort study confirms that upfront 30% irinotecan dose reductions for UGT1A1 poor metabolisers effectively prevent severe toxicity without compromising progression-free or overall survival in colorectal and pancreatic cancer p
Digital Health Literacy and Proctology: Critically Evaluating Hemorrhoid Information Quality on Chinese TikTok (Douyin)
This cross-sectional study evaluates the quality and reliability of hemorrhoid-related content on Chinese TikTok, revealing that while physician-led content is high-quality, lower-quality videos often receive higher user engagement.
Potent Viral Suppression and Safety of ALG-000184: Insights from a Phase 1 Trial in Chronic HBV Infection
This Phase 1 trial demonstrates that ALG-000184, a novel Class-E capsid assembly modulator, significantly reduces HBV DNA and RNA levels in patients with chronic hepatitis B, maintaining a favorable safety profile and supporting its potenti
Potent Antiviral Activity of the Class-E Capsid Assembly Modulator ALG-000184 in Chronic Hepatitis B: Insights from a Phase 1 Randomized Trial
This review synthesizes the Phase 1 trial findings of ALG-000184, a novel capsid assembly modulator, demonstrating significant multi-log reductions in HBV DNA and RNA with a favorable safety profile in chronic HBV patients.
Cyclic Exclusive Enteral Nutrition: A New Paradigm for Drug-Free Remission in Pediatric Crohn’s Disease
The CD-HOPE trial reveals that cyclic exclusive enteral nutrition (C-EEN) is superior to daily partial enteral nutrition (PEN) for maintaining drug-free remission in children with Crohn’s disease, providing a critical alternative to long-te
PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial
The Phase 3 CASSANDRA trial reveals that the four-drug PAXG regimen significantly improves event-free survival compared to mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, potentially redefi
Beyond MELD: The Liver Immune Frailty Index (LIFI) Predicts Post-Transplant Mortality with High Precision
Researchers have developed the Liver Immune Frailty Index (LIFI), a biomarker-based tool using fractalkine and MMP3 to predict post-liver transplant mortality. With a C-statistic of 0.83, LIFI identifies high-risk candidates, potentially tr
Long-Term Parity in Adhesiolysis: 5-Year Results from the LASSO Randomized Trial Challenge Laparoscopic Superiority
The 5-year follow-up of the LASSO randomized clinical trial demonstrates that while laparoscopic adhesiolysis offers short-term recovery benefits, it provides no significant long-term advantage over open surgery regarding SBO recurrence, in
Nearly 40 Percent of Indian Adults Impacted by MASLD: New Evidence from the Phenome India Cohort
The Phenome India study identifies a 38.9% age-adjusted prevalence **Constructing the JSON Object** Now, I’m carefully constructing the JSON object, which needs to be a valid, parseable string. I’m focusing on incorporating the main finding
Monthly Efimosfermin Alfa Demonstrates Safety and Tolerability in MASH-Related Fibrosis: Insights from a Phase 2 Trial
The Phase 2 trial of efimosfermin alfa (BOS-580) shows that once-monthly dosing is safe and well-tolerated in patients with MASH and F2/F3 fibrosis, supporting its continued clinical development as a potential liver-targeted therapy.
The Age Gap Penalty: Why Donor-Recipient Mismatch Shortens Graft Life in Adolescent Liver Transplants
A nationwide study reveals that adolescent liver transplant recipients receiving grafts from donors 10+ years older face a 12.7% reduction in 10-year graft survival. Expanding allocation radii could improve access to age-matched organs and
Time-Varying Risks in Colorectal Adenoma Recurrence: Why Histology and Demographics Demand a Personalized Surveillance Calendar
A massive cohort study reveals that colorectal adenoma recurrence risk is not static; high-grade dysplasia, villous histology, obesity, and sex-based factors exhibit distinct time-varying patterns, necessitating a shift toward personalized,
New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window
A prospective study of 18,838 adults reveals that glycemically defined new-onset diabetes (GNOD) significantly increases the 3-year risk of pancreatic cancer, with notable racial variations and a critical 8-month diagnostic window.
Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores
A Phase 2 trial of NG101 for gastroparesis missed its primary endpoint for nausea severity on the DIGS-DD scale but demonstrated significant improvements in Patient Global Impression of Change (PGIC) and a favorable safety profile, particul
Metopimazine Mesylate (NG101) in Gastroparesis: Navigating the Complexities of Nausea Management and Trial Endpoints
This Phase 2 trial of NG101 for gastroparesis did not meet its primary endpoint for nausea severity reduction but showed significant global improvement in patient-reported outcomes and a favorable safety profile, particularly in idiopathic
A Glimmer of Hope for the ‘Slow Stomach’: Exploring the New Frontier in Gastroparesis Treatment
This article examines the Phase 2 trial of NG101 (metopimazine), a novel treatment for gastroparesis. While the primary endpoint was missed, significant improvements in patient-reported outcomes and a strong safety profile suggest a potenti
Can a Peripheral Opioid Antagonist Break the Cycle of Recurrent Acute Pancreatitis? Insights from the PAMORA-RAP Trial
The PAMORA-RAP trial suggests that naldemedine, a peripherally acting μ-opioid receptor antagonist, may reduce the risk of recurrent acute pancreatitis by nearly 50%, offering a potential first-in-class pharmacological strategy for this hig
Browse by specialty
Open language-specific specialty feeds and department pages.